{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:02:44Z","timestamp":1747368164041,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ANZ Journal of Surgery"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>PSA screening is advocated in men with a life expectancy of &gt;10\u2009years. With a rising mean life expectancy of 81\u2009years in Australia, many men in their 70s have life expectancies of &gt;10\u2009years. Additionally, advanced age is an independent risk factor for high grade prostate cancer. Hence, we aimed to identify patient and disease characteristics and outcomes of men &gt;70\u2009years undergoing transperineal prostate biopsies (TPB) for suspected prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients aged 70\u2009years old and above who underwent TPB for suspected prostate cancer between 1st January 2019 and 1st July 2022 at a large tertiary centre were identified. Data including patient Charlson Comorbidity Indices (CCI), pre\u2010operative PSA, Multiparametric prostate MRI (mpMRI), histopathological results, subsequent intervention, and treatment intent (curative vs palliative) were obtained via scanned and electronic medical records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 229 patients, median age was 74\u2009years and 72.5% patients had a CCI of \u22644 (&gt;53% estimated 10\u2010year survival). 80.8% were diagnosed with prostate cancer and 65.9% had ISUP\u2009\u2265\u20092 disease. 86.4% of patients with PIRADS 4 or 5 lesions resulted in clinically significant prostate cancer. 3.9% had mild biopsy complications. 76.8% of those with prostate cancer underwent treatment with curative intent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Men &gt;70\u2009years of age have a higher risk of clinically significant prostate cancer and low biopsy risk. Hence, many may benefit from early diagnosis and treatment. Decision on screening and further investigation should be based on assessment of individual risks, benefits and life expectancy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ans.19417","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T07:29:14Z","timestamp":1738135754000},"page":"756-760","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and tumour characteristics in older patients (70\u2009years or older) undergoing transperineal prostate biopsy: a retrospective cohort study"],"prefix":"10.1111","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-9643","authenticated-orcid":false,"given":"Sean","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Urology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3575-2191","authenticated-orcid":false,"given":"Shayan","family":"Soroush","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nursing and Health Sciences Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5168-6346","authenticated-orcid":false,"given":"Gavin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Harper","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Donnellan","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weranja","family":"Ranasinghe","sequence":"additional","affiliation":[{"name":"Department of Urology Monash Health  Melbourne Victoria Australia"},{"name":"Department of Medicine, Nursing and Health Sciences Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"volume-title":"Deaths in Australia","year":"2022","author":"Australian Institute of Health and Welfare","key":"e_1_2_7_3_1"},{"key":"e_1_2_7_4_1","unstructured":"The Australian Government Actuary.Australian Life Tables 2015\u20132017.2019."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2015.56654"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02127-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ans.14166"},{"key":"e_1_2_7_8_1","unstructured":"European Association of Urology.Prostate Cancer. EAU Guidelines.2023."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.11.082"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.140"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15039"},{"key":"e_1_2_7_14_1","first-page":"999","article-title":"Risks of major long\u2010term side effects associated with androgen\u2010deprivation therapy in men with prostate cancer. Pharmacotherapy: the journal of human pharmacology and drug","volume":"38","author":"Nguyen C","year":"2018","journal-title":"Therapy"},{"key":"e_1_2_7_15_1","unstructured":"Australian Bureau of Statistics.Population: Census 2021.2022."},{"key":"e_1_2_7_16_1","unstructured":"Australian Bureau of Statistics.Melbourne \u2013 South East 2021 Census.2021."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21391"},{"key":"e_1_2_7_19_1","unstructured":"Victorian Cancer Registry.Cancer in Victoria 2021.2022."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11470.x"},{"key":"e_1_2_7_21_1","unstructured":"Australian Institute of Health and Welfare.Cancer data in Australia.2022."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100612"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.06.003"},{"key":"e_1_2_7_24_1","first-page":"181","article-title":"Frequency of Gleason score 7 to 10 in 5100 elderly prostate cancer patients","volume":"18","author":"Shah N","year":"2016","journal-title":"Rev. Urol."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12582"},{"issue":"4","key":"e_1_2_7_27_1","article-title":"A 4K score\/MRI\u2010based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer","volume":"4","author":"Wagaskar VG","year":"2021","journal-title":"Cancer Rep."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.255"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.01.014"}],"container-title":["ANZ Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ans.19417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:51:54Z","timestamp":1747291914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ans.19417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/ans.19417"],"URL":"https:\/\/doi.org\/10.1111\/ans.19417","archive":["Portico"],"relation":{},"ISSN":["1445-1433","1445-2197"],"issn-type":[{"type":"print","value":"1445-1433"},{"type":"electronic","value":"1445-2197"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}